onset of tirzepatide 💉 In a large real-world study, was associated with a lower incidence major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart Flavor:GLP-1 Craving Control Set Lipotropic Injections 4 week progress :

onset of tirzepatide 💉 In a large real-world study, was associated with a lower incidence major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart Flavor:GLP-1 Craving Control Set Lipotropic Injections 4 week progress :

4 week progress : r/Semaglutide

8.6 Renal Impairment The efficacy and safety of INVOKANA for glycemic control were evaluated in a trial that included adult patients with moderate renal impairment (eGFR 30 to less than 50 mL/min/1.73 m 2) [see Clinical Studies (14.1)]

Lipotropic Injections

Flavor:GLP-1 Craving Control Set

Understanding the Link Between Weight Loss Drugs and Hair Shedding: Hair loss on tirzepatide is not a direct side effect of tirzepatide , but rather a secondary reaction to rapid weight loss